Catalogue

Background
BCRP acts as a xenobiotic transporter that may play an important role in the exclusion of xenobiotics from the brain. May be involved in brain-to-blood efflux. Appears to play a major role in the multidrug resistance phenotype of several cancer cell lines. When overexpressed, the transfected cells become resistant to mitoxantrone, daunorubicin and doxorubicin, display diminished intracellular accumulation of daunorubicin, and manifest an ATP-dependent increase in the efflux of rhodamine 123.

Synonyms: Breast cancer resistance protein; CDw338; Mitoxantrane resistance-associated protein; Placenta-specific ATP-binding cassette transporter

Source

Immunogen: Synthetic peptide derived from human BCRP protein

Product

Product Form: Affinity Purified

Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide

Purification Method: Antigen Immunoaffinity Purification

Concentration: See vial for concentration

Applications
Antibody can be used for immunohistochemistry at 5-10 µg/ml on paraffin-embedded tissues. Optimal concentration should be evaluated by serial dilutions.

Positive Control: Highly expressed in placenta

Storage
Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Product Stability: See expiration date on vial

Shipping Conditions: Ship at ambient temperature, freeze upon arrival

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but our company accepts no liability for any inaccuracies or omissions in this information.

References
1. Zhou, W., et al. 'The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype.' Nat. Med. 2001, 7, 1028-1034. 2. Itoda, M., et al. ''Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan.' Drug Metab. Pharmacokinet. 2003, 18, 212-217. 3. Zamber, C.P., et al. 'Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine.' Pharmacogenetics 2003, 13, 19-28.

Protein Reference(s)

Database Name: UniProt

Accession Number: Q9UNQ0

Species Accession: Human

Safety Datasheet(s) for this product: